CLOSEOUT LETTER
Cytophil, Inc.
- Recipient:
- Cytophil, Inc.
United States
- Issuing Office:
United States
| |
| Food and Drug Administration Minneapolis District Office Central Region 250 Marquette Avenue, Suite 600 Minneapolis, MN 55401 Telephone: (612) 758-7185 FAX: (612) 334-4142 |
Department of Health and Human Services
October 24, 2014
William G. Hubbard
President
Cytophil, Inc.
2485 Corporate Circle, Suite 2
East Troy, Wisconsin 53120
Dear Mr. Hubbard:
The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter MIN 14-13 dated April 1, 2014. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Melissa I. Michurski
Compliance Officer
Minneapolis District
MIM/ccl